Evidence map›Paper›PMID 32905241›Full record

ArticleClinical kidney journal2020

Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated.

Michelle M Y Wong, Charlotte Tu, Yun Li, Rachel L Perlman, Roberto Pecoits-Filho, Antonio A Lopes, Ichiei Narita, Helmut Reichel, Friedrich K Port, Nidhi Sukul and 5 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical kidney journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03381950 (Chronic Kidney Disease - Renal Epidemiology and Information Network), which is not on this map. Cited by 81 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 4 pooled it
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03381950 completednot on this map

Chronic Kidney Disease - Renal Epidemiology and Information Network: The CKD-REIN Cohort

TypeobservationalSponsorInstitut National de la Santé Et de la Recherche Médicale, FranceRan2013 to 2020Enrolled3,033ConditionsRenal Insufficiency, Chronic
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 4 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
    Trial
  9. Article
  10. Review
  11. The roles of free-fatty acid receptors in the pathophysiology of renal disorders.The Journal of pharmacology and experimental therapeutics · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Different types of anemia in patients with chronic kidney disease.Pakistan journal of medical sciences · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 6 countries.

Michelle M Y WongDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Charlotte TuArbor Research Collaborative for Health, Ann Arbor, MI, USA.
Yun LiSchool of Public Health, University of Michigan, Ann Arbor, MI, USA.
Rachel L PerlmanDepartment of Nephrology, University of Michigan, Ann Arbor, MI, USA.
Roberto Pecoits-FilhoDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Antonio A LopesFaculdade de Medicina da Bahia School of Medicine, Universidade Federal da Bahia, Salvador, Brazil.
Ichiei NaritaDivision of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Science, Niigata, Japan.
Helmut ReichelNephrological Center, Villingen-Schwenningen, Germany.
Friedrich K PortArbor Research Collaborative for Health, Ann Arbor, MI, USA.
Nidhi SukulDepartment of Nephrology, University of Michigan, Ann Arbor, MI, USA.
Benedicte StengelCESP, Center for Research in Epidemiology and Population Health, Univ Paris-Saclay, Univ Paris-Sud, UVSQ, Inserm UMRS 1018, Villejuif, France.
Bruce M RobinsonArbor Research Collaborative for Health, Ann Arbor, MI, USA.
Ziad A MassyCESP, Center for Research in Epidemiology and Population Health, Univ Paris-Saclay, Univ Paris-Sud, UVSQ, Inserm UMRS 1018, Villejuif, France.
Ronald L PisoniArbor Research Collaborative for Health, Ann Arbor, MI, USA.
CKDopps Investigators
Arbor Research Collaborative for Health · USUniversity of Michigan · USInserm · FRUniversity of British Columbia · CAMichigan Medicine · USNephrologisches Zentrum Villingen-Schwenningen · DENiigata University · JPUniversidade Federal da Bahia · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInternational variation in anemia assessment and management practices in chronic kidney disease (CKD) is poorly understood.

methodsWe performed a cross-sectional analysis of anemia laboratory monitoring, prevalence and management in the prospective Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps). A total of 6766 participants with CKD Stages 3a-5ND from nephrology clinics in Brazil, France, Germany and the USA were included.

resultsAmong patients with anemia (hemoglobin <12 g/dL), 36-58% in Brazil, the USA and Germany had repeat hemoglobin measured and 40-61% had iron indices measured within 3 months of the index hemoglobin measurement. Anemia was more common in the USA and Brazil than in France and Germany across CKD stages. Higher ferritin and lower iron saturation (TSAT) levels were observed with lower hemoglobin levels, and higher ferritin with more advanced CKD. The proportion of anemic patients with ferritin <100 ng/mL or TSAT <20% ranged from 42% in Brazil to 53% in France and Germany, and of these patients, over 40% in Brazil, Germany and the USA, compared with 27% in France, were treated with oral or intravenous iron within 3 months after hemoglobin measurement. The proportion of patients with hemoglobin <10 g/dL treated with erythropoiesis-stimulating agents ranged from 28% in the USA to 57% in Germany.

conclusionsHemoglobin and iron stores are measured less frequently than per guidelines. Among all regions, there was a substantial proportion of anemic patients with iron deficiency who were not treated with iron, highlighting an area for practice improvement in CKD care.

Indexed as

anemiachronic kidney diseaseerythropoiesis-stimulating agentsiron deficiencyiron supplementation

Identifiers

PMID32905241
PMCPMC7467578
OpenAlexW2964863420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.